Drawing for LCR353

USPTO serial 79094711

LCR353

Reviewed by CopyMark Law Group

Reg. 4069257Status 404
Filing date
Status date
Registration date
Dec 13, 2011
Examiner
RAPPAPORT, SETH
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with LCR353?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Nutritional additives for medical purposes for use in foods and dietary supplements for human consumption; dietetic substances, additives, foods and beverages adapted for medical use; vitamin preparations; mineral food supplements; pharmaceutical medicines and preparations used to boost the body's immune system or used in the treatment of gastroenterological, gynecological and ear, nose and throat disorders, skin conditions and allergies; medicines and medical preparations, namely, lyophilized bacteria used in the production of biological medicinal preparations for treating intestinal and gynecological disorders, dermatological conditions, problems with the immune system and ear, nose and throat disorders, for humans; biological preparations, namely, biological preparations for regulating intestinal and vaginal flora, for the treatment of gastroenterological, gynecological and ear, nose and throat disorders, skin conditions and allergies, dermatitis, eczema, psoriasis, acne, candida, gums inflammatory diseases, sinusitis and tonsillitis, and auto-immune diseases, and chemical preparations, namely, chemical preparations for treating flatulence, intestinal spasms, gastroenterological, gynecological and ear, nose and throat disorders, skin conditions and allergies, dermatitis, eczema, psoriasis, acne, candida, gums inflammatory diseases, sinusitis and tonsillitis, and auto-immune diseases, for pharmaceutical or medical use; vaginal capsules primarily containing vaginal preparations, namely, antifungals; antifungal and antibiotic preparations, namely, antifungals and antibiotic creams, lotions, capsules; antispasmodic biological preparations for intestinal use for the treatment of intestinal diseases; pharmaceutical preparations to regulate bowel movements; biological preparations for medical use for the treatment of flatulenceSECTION 71 - CANCELLED

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jan 22, 2021DENCNOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED
Jan 22, 2021DETHDEATH OF INTERNATIONAL REGISTRATION
May 17, 2019INNTTOTAL INVALIDATION PROCESSED BY THE IB
Mar 29, 2019INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Mar 28, 2019INPCINVALIDATION PROCESSED
Mar 20, 2019INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Jul 20, 2018C71TCANCELLED SECTION 71
Jun 16, 2016ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB
May 5, 2013FINOFINAL DECISION TRANSACTION PROCESSED BY IB
Jul 18, 2012FICSFINAL DISPOSITION NOTICE SENT TO IB
Jul 18, 2012FIMPFINAL DISPOSITION PROCESSED
Apr 17, 2012GPNXNOTIFICATION PROCESSED BY IB
Mar 13, 2012FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Dec 13, 2011R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 27, 2011PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 7, 2011OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Sep 7, 2011OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Sep 7, 2011NPUBNOTICE OF PUBLICATION
Aug 26, 2011ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB
Aug 26, 2011CNEAEXAMINERS AMENDMENT MAILED
Aug 25, 2011PREVLAW OFFICE PUBLICATION REVIEW COMPLETED
Aug 25, 2011CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Aug 25, 2011XAECEXAMINER'S AMENDMENT ENTERED
Aug 25, 2011CNEAEXAMINERS AMENDMENT -WRITTEN
Aug 25, 2011ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN
Aug 5, 2011PBCRWITHDRAWN FROM PUB - OG REVIEW QUERY
Jul 22, 2011PREVLAW OFFICE PUBLICATION REVIEW COMPLETED
Jul 20, 2011CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Jul 20, 2011TEMETEAS/EMAIL CORRESPONDENCE ENTERED
Jul 20, 2011CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 14, 2011ALIEASSIGNED TO LIE
Jun 30, 2011TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 23, 2011RFNTREFUSAL PROCESSED BY IB
Apr 8, 2011MAFRAPPLICATION FILING RECEIPT MAILED
Apr 5, 2011RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Apr 5, 2011RFRRREFUSAL PROCESSED BY MPU
Apr 5, 2011RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Apr 4, 2011CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 4, 2011DOCKASSIGNED TO EXAMINER
Apr 4, 2011NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 1, 2011LIMILIMITATION FROM ORIGINAL APPLICATION ENTERED
Mar 31, 2011REPRSN ASSIGNED FOR SECT 66A APPL FROM IB

Frequently asked questions

Related guidance